Volume : 12, Issue : 06, June – 2025

Title:

IMMUNOPATHOGENESIS AND EMERGING IMMUNOTHERAPIES IN TYPE 1 DIABETES MELLITUS: THE ROLE OF TEPLIZUMAB IN DISEASE MODULATION

Authors :

Moruj Hassan Albanji*, Saud Hasan Surbaya, Ozoof Ateq Alnakhli

Abstract :

Type 1 diabetes mellitus (T1DM), a complex chronic disease with an intricate etiology and pathogenesis, involves the recognition of self-antigens by pancreatic islet autoantigen-specific T cells and plays crucial roles in both early- and late-stage destruction of beta cells, thus impacting disease progression. Antigen-specific T cells regulate and execute immune responses by recognizing antigens, playing broad roles in treating various diseases. Immunotherapy targeting antigen-specific T cells holds promising potential as a targeted treatment approach.
Aim of the study: This review outlines the pathogenesis of diabetes, emphasizing the pivotal role of pancreatic islet autoantigen-specific T cells in the progression and treatment of T1DM. Exploring this avenue in research holds promise for identifying novel therapeutic targets for effectively managing diabetes.
Materials and methods: This review is a comprehensive search of PUBMED from 2015 to 2025.
Conclusion: Type 1 diabetes is a chronic autoimmune ailment that requires a tremendous amount of medical care and lifelong follow-ups that can often become burdensome to the finances of the patients. Advancements in patient care and better treatment modalities can benefit the patient and decrease the burden on healthcare facilities. Immunotherapy is a promising approach to provide better care to such patients.
Keywords: type 1 diabetes; management; immunotherapy; teplizumab

Cite This Article:

Please cite this article in press Moruj Hassan Albanji et al., Immunopathogenesis And Emerging Immunotherapies In Type 1 Diabetes Mellitus: The Role Of Teplizumab In Disease Modulation, Indo Am. J. P. Sci, 2025; 12(06).

Number of Downloads : 10

References:

1. World Health Organization. (2016, November). Diabetes fact sheet N°312. Retrieved from [Original archived URL, if available, otherwise omit] (Archived from the original on August 26, 2013)
2. Hormazábal-Aguayo I, Ezzatvar Y, Huerta-Uribe N, Ramírez-Vélez R, Izquierdo M, & García-Hermoso A (2023). Incidence of type 1 diabetes mellitus in children and adolescents under 20 years of age across 55 countries from 2000 to 2022: A systematic review with meta-analysis. Diabetes/Metabolism Research and Reviews.
3. National Institute of Diabetes and Digestive and Kidney Diseases. (2024, October). Symptoms & causes of diabetes. https://www.niddk.nih.gov/health-information/diabetes/overview/symptoms-causes?dkrd=hiscr0005
4. Misra S, & Oliver N S (2015). Diabetic ketoacidosis in adults. BMJ (Clinical research ed.), 351, h5660.
5. Centers for Disease Control and Prevention. (2024, May 15). Diabetic Ketoacidosis. https://www.cdc.gov/diabetes/about/diabetic-ketoacidosis.html
6. Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson B J, Jacobsen L M, Schatz D A, & Lernmark Å (2017). Type 1 diabetes mellitus. Nature reviews. Disease primers, 3, 17016.
7. Campbell-Thompson M L, Atkinson M A, Butler A E, Chapman N M, Frisk G, Gianani R, Giepmans B N, von Herrath M G, Hyöty H, Kay T W, Korsgren O, Morgan N G, Powers A C, Pugliese A, Richardson S J, Rowe P A, Tracy S, & In’t Veld P A (2013). The diagnosis of insulitis in human type 1 diabetes. Diabetologia, 56(11), 2541–2543
8. Campbell-Thompson M. (2015). Organ donor specimens: What can they tell us about type 1 diabetes?. Pediatric diabetes, 16(5), 320–330. https://doi.org/10.1111/pedi.12286
9. DiMeglio L A, Evans-Molina C, & Oram R A (2018). Type 1 diabetes. Lancet (London, England), 391(10138), 2449–2462.
10. American Diabetes Association (2018). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes care, 41(Suppl 1), S13–S27.
11. American Diabetes Association. (2018). 3. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes—2018. Diabetes Care, 41(Supplement_1), S28–S37.
12. Norris J M, Johnson R K, & Stene L C (2020). Type 1 diabetes-early life origins and changing epidemiology. The lancet. Diabetes & endocrinology, 8(3), 226–238.
13. American Diabetes Association. (2021). 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care, 44(Supplement_1), S15–S33.
14. Butler A E, & Misselbrook D (2020). Distinguishing between type 1 and type 2 diabetes. BMJ (Clinical research ed.), 370, m2998.
15. Libman I M, Miller K M, DiMeglio L A, Bethin K E, Katz M L, Shah A, Simmons J H, Haller M J, Raman S, Tamborlane W V, Coffey J K, Saenz A M, Beck R W, Nadeau K J, & T1D Exchange Clinic Network Metformin RCT Study Group (2015). Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. JAMA, 314(21), 2241–2250.
16. Otto-Buczkowska E, & Jainta N (2017). Pharmacological Treatment in Diabetes Mellitus Type 1 – Insulin and What Else?. International journal of endocrinology and metabolism, 16(1), e13008.
17. Warshauer J T, Bluestone J A, & Anderson M S (2020). New Frontiers in the Treatment of Type 1 Diabetes. Cell metabolism, 31(1), 46–61.
18. Jeun R. (2025). Immunotherapies for prevention and treatment of type 1 diabetes. Immunotherapy, 17(3), 201–210.
19. Herold K C, Gitelman S E, Gottlieb P A, Knecht L A, Raymond R, & Ramos E L (2023). Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. Diabetes care, 46(10), 1848–1856.
20. Long S A, Thorpe J, DeBerg H A, Gersuk V, Eddy J, Harris K M, Ehlers M, Herold K C, Nepom G T, & Linsley P S (2016). Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Science immunology, 1(5), eaai7793.
21. Lledó-Delgado A, Preston-Hurlburt P, Currie S, Clark P, Linsley P S, Long S A, Liu C, Koroleva G, Martins A J, Tsang J S, & Herold K C (2024). Teplizumab induces persistent changes in the antigen-specific repertoire in individuals at risk for type 1 diabetes. The Journal of clinical investigation, 134(18), e177492.
22. Herold K C, Bundy B N, Long S A, Bluestone J A, DiMeglio L A, Dufort M J, Gitelman S E, Gottlieb P A, Krischer J P, Linsley P S, Marks J B, Moore W, Moran A, Rodriguez H, Russell W E, Schatz D, Skyler J S, Tsalikian E, Wherrett D K, Ziegler A G, … Type 1 Diabetes TrialNet Study Group (2019). An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. The New England journal of medicine, 381(7), 603–613.
23. Sims E K, Bundy B N, Stier K, Serti E, Lim N, Long S A, Geyer S M, Moran A, Greenbaum C J, Evans-Molina C, Herold K C, & Type 1 Diabetes TrialNet Study Group (2021). Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Science translational medicine, 13(583), eabc8980.
24. Nourelden A Z, Elshanbary A A, El-Sherif L, Benmelouka A Y, Rohim H I, Helmy S K, Sayed M K, Ismail A, Ali A S, Ragab K M, & Zaazouee M S (2021). Safety and Efficacy of Teplizumab for Treatment of Type One Diabetes Mellitus: A Systematic Review and Meta-Analysis. Endocrine, metabolic & immune disorders drug targets, 21(10), 1895–1904.
25. Grando Alves G, Cunha L, Henkes Machado R, & Lins de Menezes V (2024). Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials. Diabetes, obesity & metabolism, 26(7), 2652–2661.
26. Long S A, Thorpe J, DeBerg H A, Gersuk V, Eddy J, Harris K M, Ehlers M, Herold K C, Nepom G T, & Linsley P S (2016). Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes. Science immunology, 1(5), eaai7793.
27. Provention Bio Inc (2023, December). Tzield (teplizumab-mzwv) injection: Full prescribing information. Bridgewater, NJ.
28. Salame G, Hakim V, Dagher C, Daou R M, Dada A E, Nassif L, Ghadieh H E, Azar S, Bazzi S, & Harb F (2025). Immunotherapy as a treatment for type 1 diabetes mellitus in children and young adults: A comprehensive systematic review and meta-analysis. PloS one, 20(4), e0321727.
29. O’Donnell H K, Simmons K M, Gitelman S E, Dex T, Hill R, Wieloch M, Zaccai J, D’Souza J, Ginchereau Sowell F, Turnbull J, & Hood K K (2025). Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes. Diabetes, obesity & metabolism, 27(5), 2495–2506.